Mitigate risks in clinical trials

Potentially valid drugs are sometimes denied FDA approval because flawed clinical data undermines efficacy and safety findings, says Health Decisions. The company notes that risk is at an all-time high in clinical development. In a new white paper, the group describes factors that make some trials riskier than others, as well as systematic risk mitigation. Release